The first-ever daily pill to help prevent against HIV was approved Monday by US regulators for use in uninfected adults who are at risk for getting the virus that causes AIDS.
Truvada, made by Gilead Sciences in California, has been on the market since 2004 and was approved by the Food and Drug Administration for a new use as a tool to help ward off HIV in otherwise healthy people, in combination with safe sex and regular testing.
The pill as pre-exposure prophylaxis (PrEP) has been hailed by some AIDS experts as a potent new tool against human immunodeficiency virus, but some health care providers are concerned it could encourage risky sex behavior.
In addition, the regimen is estimated to cost around $14,000 per year, making it out of reach of many.
“Truvada alone should not be used to prevent HIV infection,” said Debra Birnkrant, director of the division of antiviral products at the FDA.
“Truvada as PrEP represents another effective, evidence-based approach that can be added to other prevention methods to help reduce the spread of HIV.”
The FDA said Truvada should be used as “part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing.”
Truvada was previously approved as a treatment for people infected with HIV to be used in combination with other antiretroviral drugs.
The decision by the FDA followed the advice of an independent panel in May that supported Truvada for prevention in uninfected people, after clinical trials showed it could lower the risk of HIV in gay men and heterosexual couples.
One study on Truvada, called the iPrEx trial, published in 2010 in the New England Journal of Medicine included 2,499 men who were sexually active with other men but were not infected with the virus that causes AIDS.
Participants were selected at random to take a daily dose of Truvada — a combination of 200 milligrams of emtricitabine and 300 milligrams of tenofovir disoproxil fumarate — or a placebo.
Those in the study who took the drug regularly had almost 73 percent fewer infections. Across the entire study, including those who had not been as diligent in taking Truvada, there were 44 percent fewer infections than in those who took a placebo.
A second study on 4,758 heterosexual couples in which one partner was infected with HIV and the other was not, showed that Truvada reduced the risk of becoming infected by 75 percent compared with a placebo.
Experts have described the results as game-changing and the first demonstration that an already-approved oral drug could decrease the likelihood of HIV infections.
Common side effects were the same as experienced by people with HIV who were taking Truvada, and included diarrhea, nausea, abdominal pain, headache, and weight loss.
However, adherence rates — meaning how often people in the study actually took the drug daily — were low in the study of men who have sex with men, just 30 percent, Birnkrant said.
In the study of heterosexual partners, adherence was much higher, between 80 and 90 percent.
Therefore, the drug label must include special instructions for health care providers on how to counsel potential users of the drug.
The drugmaker must also include a warning that Truvada for PrEP “must only be used by individuals who are confirmed to be HIV-negative prior to prescribing the drug and at least every three months during use.”
Gilead Sciences is also required to collect samples from people who test positive for HIV while taking the drug and analyze them for signs of drug resistance.
As to concerns about whether the pill might boost risky sex practices and lead people to abandon condoms as a first line of protection, Birnkrant said the studies have not shown that so far.
“We don’t really have any strong evidence to show that condoms were not used or that there was a decrease in condom use when Truvada was used,” she told reporters.
The goal of the approval is to eventually cut back on the rate of new infections in the United States, which have stayed steady in recent years at about 50,000 annually, she said.
A key goal of the US strategy against HIV/AIDS, set forth in 2010, is to decrease the number of new infections by 25 percent by 2015.
“The hope is that over time it will decrease the rate of new infections or incidence in the United States.”
Headlines Newsview all
Suspected Boko Haram militants killed nearly 150 people in northeastern Nigerian villages, mowing down men and children while they prayed in mosques and shooting women ...
President Muhamadu Buhari on Thursday appointed Mr. Lawal Musa Daura as the new Director-General of the Department of State Security Service. He is to take over ...
Kaduna state governor, Mallam Nasir El Rufai has slammed claims he declared his assets to be worth N90 billion and 40 houses in the FCT. ... Full story
Rate this article
- Video Footage Of 2nd Jos Bomb Blast
- Listen To Leaked Call Of Jim Iyke Cursing Out Emma Agu
- Wale Expected Back In Nigeria Soon To Release A Track With Olamide
.With Land Rover 3 In as much as some say they can’t get married to celebrities because of one reason or the other, some that are ...
Omotola Jalade and Genevieve Nnaji Formed a Group to Stay Away from Each Otherâ€¦ American cinematographer, Keith L. Smith Reveals
American cinematographer that shot the award-winning movie, ‘Ije,’ Keith L. Smith, has disclosed that Nollywood duo of Omotola Jalade-Ekeinde and Genevieve Nnaji, continued with their ...
Nigerian veteran Reggae singer, Majek Fashek, has been in the news steadily for some weeks now over the poor state of his health which has ...
All is set for Hollywood movie icon, Danny Glover, to thrill and entertain Nigeria movie lovers in a home video. The foreign actor has been connected ...
NFC Exclusive: I Feel So Fulfilled Marrying An Igbo Guy- Sonia Morales, IK Ogbonna's Wife Gushes (Photos)
Nollywood actor cum model, IK Ogbonna, few days ago signed the dotted lines with his baby mama, Sonia Morales. The couple who had welcomed a son ...
Fair and beautiful Nollywood actress, Mercy Aigbe-Gentry has been confirmed to be expecting another child for her new hubby. The 'Osas' movie star, who is happily ...
Nigerian singer, Omawumi aka Omowonder, has shared a throwback picture of herself in 2002, where she was seen dressed in skirt and blouse while in ...
Mavin Records trio of Reekado Banks, Aphro Dija and Korede Bello have just landed a mouth watering deal with one of a telecommunication giant in ... Full story
Free agent Al-Farouq Aminu has reportedly joined the Portland Trail Blazers in a four-year deal for $30m. The Nigeria forward was linked with prospective clubs, which ... Full story